We evaluated DIS3 expression in PCs of MM patients from multiple cohorts, including two cohorts of newly diagnosed MM patients treated with high doses of melphalan and autologous stem cell transplantation (total therapy 2 (TT2) and Heidelberg-Montpellier (HM)), and a cohort of patients at relapse treated with bortezomib monotherapy (Mulligan cohort). The gene discussed is DIS3; the disease is Miyoshi myopathy.